Fidelity’s FHLC offers lower costs and a higher dividend yield than Invesco’s PJP, appealing to cost-conscious and income-focused investors.
The Fidelity MSCI Health Care Index ETF (FHLC) undercuts the Invesco Pharmaceuticals ETF (PJP) on fees, charging a lower expense ratio while delivering a higher trailing-12-month dividend yield. FHLC has paid $1.02 per share in dividends over the past year, compared to PJP’s incomplete distribution data.
FHLC tracks a broad U.S. healthcare index with over 300 holdings, including Eli Lilly, Johnson & Johnson, and AbbVie. PJP, launched in 2005, focuses narrowly on pharmaceuticals with just 33 securities, such as Abbott Laboratories and Amgen. FHLC’s broader diversification may reduce sector-specific risk for long-term investors.
Beta measurements indicate FHLC’s volatility relative to the S&P 500, though specific figures were not disclosed. The fund’s cost efficiency and income potential position it as a competitive option for healthcare exposure.